Monthly Archives: October 2015


Stem Cell Clinic > 2015 > October

colorado- StemCell Doctors

By Stem Cell Doctors

Experimental treatment kills off, then resets the immune system

WebMD News from HealthDay

By Dennis Thompson

HealthDay Reporter

MONDAY, Dec. 29, 2014 (HealthDay News) An experimental therapy that kills off and then resets the immune system has given three years of remission to a small group of multiple sclerosis patients, researchers say.

About eight in 10 patients given this treatment had no new adverse events after three years. And nine in 10 experienced no progression or relapse in their MS, said lead author Dr. Richard Nash of the Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center in Denver.

I think we all think of this as a viable therapy, Nash said. We still need to perform a randomized clinical trial, but were all pretty impressed so far, in terms of what weve seen.

In multiple sclerosis, the bodys immune system for some unknown reason attacks the nervous system, in particular targeting the insulating sheath that covers the nerve fibers, according to the U.S. National Institutes of Health. People with the more common form, called relapsing-remitting MS, have attacks of worsening neurologic function followed by partial or complete recovery periods (remissions).

Over time, as the damage mounts, patients become physically weak, have problems with coordination and balance, and suffer from thinking and memory problems.

This new therapy seeks to reset the immune system by killing it off using high-dose chemotherapy, then restarting it using the patients own blood stem cells. Doctors harvest and preserve the patients stem cells before treatment, and re-implant them following chemotherapy.

Originally posted here: Stem Cell Therapy for MS Shows Promise

More:
colorado- StemCell Doctors

Platelet Rich Plasma Injections – Sports Medicine Specialists

By Platelet Rich Plasma Injections

WHAT IS IT

Platelet Rich Plasma or at is affectionately called Blood Spinning is the newest procedure in the Sports Medicine Physicians arsenal. While this procedure has been used in the dental field for many years it has only become available as an office procedure in Sports Medicine over the last couple of years.

The procedure initially involves taking a specific amount of blood. The blood is then placed in a centrifuge and spun down into layers. The platelet poor plasma is withdrawn and we are left with a small portion of platelet rich plasma. We then have a concentration of platelets which is 3-5 times the concentration in normal blood. This small concentration is then injected into the injured area.

There are three main types of cells in blood. Red blood cells carry oxygen to tissues. White blood cells fight infection. The third type of cells are platelets. While we mostly think about palettes function in stopping bleeding they play a very important role in healing damaged tissue. Platelets are full of intrinsic growth factor (more than 30) and other morphologic hormones that stimulate healing of damaged tissue. All of these factors are important in the role of cell replication, angiogenesis, fibroblasts, neovascularization and collagen production. All these activities contribute to the repair of tendon, skeletal muscle and bone.

The concept if the PRP injection is to stimulate the body to potentiate a healing response. PRP has been shown to recruit reparative cells. PRP is injected in an inactivated form and once injected into the body it is activated by collagen within connective tissue. The PRP then releases its growth factors and cytokines. These in turn stimulate local stem cells. The PRP also inhibits excess inflammation which causes scar tissue. The end result is healing of tissue to its as normal as possible physiologic state.

PRP can be used both in acute and chronic conditions. In the acute phase it can get an athlete back on to the playing field faster with better and quicker healing of tissues. In chronic conditions it is used to jump start the body to heal tissue that the body has failed to heal and the healing response has stalled?

PRP is can be utilized on any muscle or tendon but the following are the most common parts injected.

As PRP as an office procedure is fairly new the research on its effectiveness is just starting to appear. The difficulty is that there are several different types of methods to prepare the PRP and they all vary on their concentration of platelets and other components that are to be injected. That being said there are now several papers indicating a very promising response to treatment. Those of us in the fields who are most experienced have all seen (although not in all) excellent results.

A small amount of blood is withdrawn from your body (20-60 ccs). This blood is mixed with an anti-coagulant and then placed in a special centrifuge and double spun. The platelet poor plasma is withdrawn leaving a small concentration of platelet rich plasma. This amount (3-10 ccs) is injected into the injured tissue. This is almost always done under the control of ultrasound guided injection to ensure we are placing their PRP exactly into the injured tissue. This is usually followed by an injection of a prepared thrombin clot which acts liked a matrix to hold the PRP fluid in the injured area.

Unlike cortisone injection where you may have an immediate response from the anti-inflammatory effect the PRP injection is stimulation a proper healing response within the bodies tissues. The healing response works over 6-8 weeks so it may be 8-12 weeks before you feel the total effects of the injection. Depending on the area injected and the severity and chronicity of the problem one or two subsequent injections may be necessary. A good program of physical rehabilitation is required to full rehabilitate the body back to full functional capacity.

As this is a medical procedure generally not covered under extended health insurance plans unless you have a discretionary component of your plan to use as you desire.

See the original post here:
Platelet Rich Plasma Injections - Sports Medicine Specialists

PRP Injections | Platelet Rich Plasma Treatment for Heel Pain

By Platelet Rich Plasma Injections

Platelet Rich Plasma injections are also known as PRP injections, used to treat chronic heel pain.

PRP is plasma with many more platelets than what is typically found in blood. Although a liquid, blood (plasma) contains solids called red cells, white cells, and platelets. Best known for clotting, platelets also contain proteins called growth factors which are very important to the healing of injuries. In a PRP injection, the concentration of platelets and growth factors is 5-10 times greater than in normal blood.

How PRP works

When we injure ourselves, blood rushes to the damaged tissue and starts an inflammatory response to start the healing cycle. Inside and on the walls of platelets are hundreds of growth factors that tell the body what to do, including stem cells. When PRP comes in contact with the injured area it turns on the DNA in those cells to cause that tissue to repair itself and make new cells. It also attracts other stem cells to the region to attach to the injured tissue to create new tissue.

What injuries are treated with PRP Injections?

How is the PRP injection made? A small amount of your blood is drawn, which is run through a centrifuge. The centrifuge separates the platelets from the rest of the blood and increases the concentration of the platelets. The increased and concentrated platelets are combined with the remaining blood to create the PRP injection.

How many PRP injections will I need?

Depending on how severe your injury is, it may take 3-7 treatments given 4-6 weeks apart to eliminate your pain and heal your injury.

After the PRP Injection

Since the PRP causes a healing inflammatory response there is usually some mild pain and swelling later that day which can be controlled with rest, ice, and if necessary, over the counter pain medication like tylenol (acetaminophen). Anti-inflammatories and steroids should not be used, as an inflammation response is necessary for the PRP to work.

The following day, light exercise is encouraged to prevent stiffness, with discomfort usually gone in 3-5 days. Painfrom the original injury may start to diminish in 1-2 weeks, but frequently it takes 3-4 treatments to know if it will work for you.

Returning to your level of pre-injury activity depends on the extent of the injury and tissue damaged.

Like Loading...

Follow this link:
PRP Injections | Platelet Rich Plasma Treatment for Heel Pain

A Journey Through A Stem Cell Transplant for Amyloidosis …

By Stem Cell Medical Center

http://www.mslaw.edu Assistant Dean Diane Sullivan documents her personal struggle with AL Amyloidosis, a rare hematological disorder and the stem cell transplant that saved her life.

Professor Sullivan, along with her closest friends and family, bring us with them as Diane journeys from diagnosis through multiple phases of treatment to recovery, on this episode of The Massachusetts School of Law's Educational Forum.

The episode includes detailed conversations, with Dr. David Seldin MD, Chief of Hematology and Oncology at BU Medical Center, and Dr. Vaishali Sanchorawala MD, Clinical Director of the stem cell transplantation program at BU Medical Center. Diane, the doctors and her family discuss the treatment process, including cryotherapy and Mucositis, chemotherapy as well as the differences between and benefits of Allogenic stem cell transplants and Autogenic stem cell transplants, as well as the importance of early diagnosis.

Professor Sullivan details how family, close friends, and colleagues were crucial to her process, and concludes with a list of lessons learned from the experience; laugh as much as possible, be kind, stay strong, hold onto hope, and have no self pity.

Professor Sullivan has returned to teaching at MSL and to walking her beloved dogs.

The Massachusetts School of Law also presents information on important current affairs to the general public in television and radio broadcasts, an intellectual journal, conferences, author appearances, blogs and books.

THE MASSACHUSETTS SCHOOL OF LAW IS NEW ENGLANDS MOST AFFORDABLE AND DIVERSE LAW SCHOOL. We are dedicated to growing tomorrows leaders; empowering them with professional skills taught by instructors with real world experience, in a fun supportive campus environment. _

YOUR FUTURE STARTS HERE! Learn More at http://MSLaw.EDU

Connect with MSLaw:

Facebook: https://www.facebook.com/MSLAndover Twitter: http://Twitter.com/EDU_video Visit our site: http://MSLaw.edu

and - Subscribe to our Videos! http://www.youtube.com/subscription_c...

-~-~~-~~~-~~-~- The History of Iran / US Relations: "American Imperialism - Stephen Kinzer on Overthrow Part 2: Vietnam, Iran and Chile" https://www.youtube.com/watch?v=y7wEC... -~-~~-~~~-~~-~-

Read more from the original source:
A Journey Through A Stem Cell Transplant for Amyloidosis ...

Myths and Misconceptions About Stem Cell Research …

By Embryonic Stem Cells

En Espaol

There is no shortage of myths and misconceptions when it comes to stem cell research and regenerative medicine. Here we address the most common concerns.

If you have more questions that aren't addressed here, please visit our other Stem Cell FAQ pages.

Is CIRM-funded stem cell research carried out ethically? Where do the embryos come from to create stem cell lines? I'm opposed to abortion. Can embryonic stem cell lines come from aborted fetuses? Does creating stem cell lines destroy the embryo? Are adult stem cells as goodor betterthan embryonic stem cells? Don't iPS cells eliminate the need to use embryos in stem cell research? Can't stem cell research lead to human cloning?

Stem cell research, like field within biomedicne, poses social and ethical concerns. CIRM, as well as the broader research community, takes these seriously.

As a state funding body, CIRM has comprehensive policies to govern research, similar to our national counterpart, the National Institutes of Health. CIRM-funded researchers must comply with a comprehensive set of regulations that have been carefully developed and are in accordance with national and international standards.

These regulations were among the first formal policies governing the conduct of stem cell research and are in accordance with recommendations from the National Academies and from the International Society for Stem Cell Research. CIRMs Standards Working Group meets regularly to consider new ethical challenges as the science progresses and to revise standards to reflect the current state of the research.

Find out More:

CIRM regulations National Academies of Science guidelines International Society for Stem Cell Research guidelines National Academies of Science podcast about guidelines for embryonic stem cell research More about CIRM-grantee ethics training (4:03)

All the human embryonic stem cell lines currently in use come from four to five day-old embryos left over from in vitro fertilization (IVF) procedures. In IVF, researchers mix a man's sperm and a woman's eggs together in a lab dish. Some of those eggs will become fertilized. At about five days the egg has divided to become a hollow ball of roughly 100 cells called a blastocyst which is smaller than the size of the dot over an i. It is these very early embryos that are implanted into the woman in the hopes that she becomes pregnant.

Each cycle of IVF can produce many blastocysts, some of which are implanted into the woman. The rest are stored in the IVF clinic freezer. After a successful implantation, they must decide what to do with any remaining embryos. There are a few options:

Some embryonic stem cell lines also come from embryos that a couple has chosen not to implant because they carry harmful genetic mutations like the ones that cause cystic fibrosis or Tay Sachs disease. These are discovered through routine genetic testing prior to implantation. Still other embryos might be malformed in some way that causes them to be rejected for implantation into the mother. Embryos with genetic defects of malformations would have been discarded if the couple had not chosen to donate them to stem cell research.

People who donate leftover embryos for research go through an extensive consent process to ensure that they understand embryonic stem cell research. Under state, national and international regulations, no human embryonic stem cell lines can be created without explicit consent from the donor.

Policies vary as to whether women may be paid or otherwise compensated to donate eggs. Most jurisdictions allow donors to be reimbursed for direct costs such as travel to the clinic or lodging. Some also allow payments or IVF services to be provided to egg donors.

Find out More:

How do scientists create stem cell lines from left over IVF embryos? (4:11)

No. Emybronic stem cells only come from four to five day old blastocysts or younger embryos.

In most cases, yes. The hollow blastocystwhich is where embryonic stem cells come fromcontains a cluster of 20-30 cells called the inner cell mass. These are the cells that become embryonic stem cells in a lab dish. The process of extracting these cells destroys the embryo.

Dont forget that the embryos were donated from IVF clinics. They had either been rejected for implantation and were going to be destroyed, or the couple had decided to stop storing the embryos for future use. The embryos used to create embryonic stem cell lines were already destined to be destroyed.

There is, however, a second method that creates embryonic stem cell lines without destroying the embryo. Instead, scientists take a single cell from a very early stage IVF embryo and can use that one cell to develop a new line. The process of removing one cell from an early stage embryo has been done for many years as a way of testing the embryo for genetic predisposition to diseases such as Tay Sachs. This process is called preimplantation genetic testing.

Adult stem cells are extremely valuable and have great potential for future therapies. However, these cells are very restricted in what they can do. Unlike embryonic stem cells, which can grow into virtually any cell type in the body, adult stem cells can only follow certain paths.

For example, Blood-forming stem cells can grow into mature blood cells, and brain stem cells may be able to grow into mature neurons, but a blood-forming stem cell cant grow into a neuron, and vice versa. Whats more, adult stem cells dont grow indefinitely in the lab, unlike embryonic stem cells, and they arent as flexible in the types of diseases they can treat.

And, while the news is full of stories about people who had great results from adult stem cell therapies, few of these therapies are part of big trials that can test whether a potential therapy is safe and effective. Until some of these large trials take place with both adult and embryonic stem cells we won't know which type of stem cell is superior. Even researchers who study adult stem cells advocate working with embryonic cells as well.

CIRM is excited about their potential for treating some diseases. However, our goal is to accelerate new treatments for diseases in need. At this time the most effective way of doing that is by exploring all types of stem cells. That's why CIRM has funded researchers pursuing a wide range of approaches to finding cures for diseases.

See how much of CIRM's funding has gone to different types of stem cells here: Overview of CIRM Stem Cell Research Funding.

Filter our list of all funded CIRM grants to see awards using different cell types.

How are adult stem cell different from embryonic stem cells? (3:29)

Induced pluripotent stem cells, or iPS cells, represent another type of cell that could be used for stem cell research. . iPS cells are adult cellsusually skin cellsthat scientists genetically reprogram to appear like embryonic stem cells. The technology used to generate human iPS cells, pioneered by Shinya Yamanaka in 2007, is very promising, which is why CIRM has funded many grants that create and use these cells to study or treat disease. However, iPS cell technology is very new and it is still not known whether those cells have the same potential as human embryonic stem cells or whether the cells are safe for transplantation.

Many CIRM-funded researchers are working to find better ways of creating iPS cells that are both safe and effective. In the mean time, waiting for iPS cells to become therapeutically safewhich will likely take yearswould slow the search for disease treatments. Cures cant wait, which is why CIRM funds all types of stem cell research.

Experts agree that research on all types of stem cells is critical. In September 2008, a panel of experts convened by the U.S. National Academy of Sciences stated that the use of human embryonic stem cells is still necessary. As panel chair Richard Hynes of the Massachusetts Institute of Technology stated:

It is far from clear at this point which types of cell types will prove to be the most useful for regenerative medicine, and it is likely that each will have some utility.

See a video about creating iPS cells (3:40)

No. Every significant regulatory and advisory body has restrictions on reproductive cloning. The National Academy of Sciences has issued guidelines banning the technique as has the International Society for Stem Cell Research. The California constitution and CIRM regulations specifically prohibit reproductive cloning with its funding.

Updated 1/15

View post:
Myths and Misconceptions About Stem Cell Research ...

Cell Therapy & Regenerative Medicine – University of Utah …

By Uncategorized

About Us

Learn more about Cell Therapy & Regenerative Medicine.

What is a Neurosphere?

CTRM provides services to develop and manufacture novel cellular therapy.

The Cell Therapy and Regenerative Medicine Program (CTRM) at the University of Utah provides the safest, highest quality products for therapeutic use and research. Our goals are to facilitate the availability of cellular and tissue based therapies to patients by bridging efforts in basic research, bioengineering and the medical sciences. As well as assemble the expertise and infrastructure to address the complex regulatory, financial and manufacturing challenges associated with delivering cell and tissue based products to patients.

To support hematopoietic stem cell transplants and to deliver innovative cellular and tissue engineered products to patients by providing comprehensive bench to bedside services that coordinate the efforts of clinicians, researchers, and bioengineers.

Product quality, safety and efficacy; Optimization of resource utilization; Promotion of productive collaborations; Support of innovative products; and Adherence to scientific and ethical excellence.

The Center of Excellence for the state of Utah that translates cutting-edge cell therapy and engineered tissue based research into clinical products that extend and improve the quality of life of individuals suffering from debilitating diseases and injuries.

More here:
Cell Therapy & Regenerative Medicine - University of Utah ...

Stem Cell Transplantation for Cancer Treatment | CTCA

By Stem Cell Treatment

Stem cell transplantation

Our Hematology Oncology Department provides advanced medical therapies for patients with various types and stages of hematologic disease, including leukemia, multiple myeloma, non-Hodgkin lymphomaand Hodgkin lymphoma. Some hematologic cancer patients undergo a hematopoietic progenitor cell transplantation (commonly referred to as a stem cell transplant).

A stem cell transplant can be used to infuse healthy stem cells into the body to stimulate new bone marrow growth, suppress the disease, and reduce the possibility of a relapse.

Stem cells can be found in the bone marrow, circulating blood (peripheral blood stem cells), and umbilical cord blood.

Our doctors perform two main types of stem cell transplants:

Before a stem cell transplant, you'll undergo a conditioning regime, which involves intensive treatment to destroy as many cancer cells as possible. You may receive high doses of chemotherapy and, in some cases, radiation therapy. Once this preparative regime is complete, you're ready to undergo the transplant.

Much like a blood transfusion, youll receive the stem cells intravenously. The procedure takes about an hour. After entering the bloodstream, the stem cells travel to the bone marrow and start to make new blood cells in a process known as engraftment.

In the months following the transplant, your care team will monitor your blood counts. You may need transfusions of red blood cells and platelets. Sometimes, the intensive treatments you receive before the stem cell transplantation can cause side effects, like infection. In this case, your doctor may administer IV antibiotics.

If you had an allogeneic stem cell transplant, your doctor may prescribe certain drugs to reduce the risk of graft-versus-host-disease (GVHD), a condition where the donated cells attack the patient's tissues.

Recovery from a stem cell transplant can take several months. Youll need support from multiple areas to help reduce side effects, keep you strong and improve your quality of life.

Our hematology oncology team will collaborate with the rest of your care team to support you throughout the entire treatment process. The following are examples of how the other members of your care team will work together to meet your individual needs:

Throughout your treatment, your care manager will also be available to make sure your questions are answered, and ensure you and your family have the information and resources you need to make informed decisions.

Stem cells are parent cells which can develop into any of the three main types of blood cells: red blood cells, white blood cells and platelets.

A peripheral blood stem cell transplant (PBSCT) uses stem cells extracted from the peripheral (circulating) blood supply.

A bone marrow transplant (BMT) uses stem cells collected from the bone marrow.

Continue reading here:
Stem Cell Transplantation for Cancer Treatment | CTCA

CAPMM Team | Center for Applied Proteomics and Molecular …

By Stell Cell Research

Co-Directors

Lance A. Liotta, MD, PhD Co-Director

Emanuel Petricoin III, PhD Co-Director

Peggy Hackett Assistant to Center Directors Email: phackett@gmu.edu Phone: (703) 993-9526

Carly Stell Senior Grants Administrator, Office of Sponsored Programs Email: cstell@gmu.edu

Valerie Calvert, BS Research Assistant Professor Email: vcalvert@gmu.edu

Jianghong Deng, MS Biostatistician Email: jdeng@gmu.edu

Jianghong specializes in medical diagnostic tests, sample size calculation, survival analysis, predictive model development and high-dimensional data analysis technology. A user of SAS, R, and JMP, Jianghong is a member of the American Statistical Association and the American Association for Cancer Research.

Virginia Espina, PhD, MT(ASCP) Research Assistant Professor Email: vespina@gmu.edu

Dr. Virginia Espina is the former Manager of the Laser Capture Microdissection Core facility at the National Institutes of Health/National Cancer Institute, within the Laboratory of Pathology and the NCI-FDA Clinical Proteomics Program. Dr. Espina's career began as a Medical Technologist in clinical laboratories. She has extensive clinical laboratory experience, including clinical chemistry and Blood Bank. Her thorough knowledge of clinical quality control and quality assurance issues and regulations compliment her clinical research initiatives, which include phosphoprotein stability, effects of therapy on protein cell signaling pathways, and live cell/tissue microdissection. She currently has multiple roles in the Center for Applied Proteomics and Molecular Medicine, including CAP/CLIA laboratory director, research laboratory manager, instructor, and researcher. In varying degrees, she has been involved in a number of functional proteomics-based research projects and clinical trials at George Mason University and the National Institutes of Health/National Cancer Institute. The studies performed by Dr. Espina have involved a wide spectrum of proteomic approaches, including classical western blotting, laser capture microdissection and reverse phase protein microarrays, that yielded elucidation of phosphorylation specific kinase events in the tumor-host microenvironment of multiple myeloma, breast, lung and ovarian cancer. Dr. Espinas responsibilities include lab management for the CAP/CLIA compliant clinical trial laboratory, co-PI on a Breast DCIS chemoprevention clinical trial, as well as translational research involving nanoparticle applications for harvesting biomarkers, identification of breast cancer progenitor cells in pre-invasive lesions, and elucidation of cell signaling cascades in cancer and infectious disease. Dr. Espina is the lead scientist developing phosphoprotein preservatives as an alternative to formalin fixation.

Isela Gallagher, MS Research Specialist Email:rgallag3@gmu.edu

Iselas research incorporates laser capture microdissection, reverse phase protein microarrays, western blotting, and immunohistochemistry to investigate unique signaling pathway profiles in cancer tissue that can be utilized for diagnosis, prognosis, targeted therapeutics and individualized therapy.

Alessandra Luchini, PhD Assistant Professor Email: aluchini@gmu.edu

Claudius Mueller, PhD Research Assistant Professor Email: cmuelle1@gmu.edu Claudius' research focuses on protein pathway activation mapping in brain cancer (glioblastoma) as well as the development and optimization of new tissue stabilizing chemistries and fixatives that preserve the phosphorylation state of signaling proteins, while maintaining full diagnostic immunohistochemical and histomorphologic detail of cells and tissues.

Mariaelena Pierobon, MD Research Assistant Professor Email:mpierobo@gmu.edu

Alex Reeder, BS , MT(ASCP) Medical Technologist Email:kreeder@gmu.edu Alex is involved in research that focuses on translational breast cancer clinical trials. She uses laser capture microdissection, reverse phase protein microarrays and cell culture as primary technologies in her work. Alex analyzes protein signaling pathways in tissue to provide physicians with data to rationally select FDA-approved pharmaceutical treatments for breast cancer patients.

Sally Rucker, BS, MT(ASCP) Medical Technologist Email: srucker@gmu.edu Sally is involved in research that uses hydrogel microparticles to sequester and concentrate low abundance proteins, such as biomarkers or antigens, in complex biofluid samples. Her current focus is on early Lyme disease detection using these microparticles to concentrate Lyme antigens in urine, which can then be detected using an ELISA procedure. Sally also ensures the laboratory is CAP/CLIA compliant for upcoming clinical trials. This involves meeting all CAP/CLIA regulations and participating in proficiency testing surveys to monitor the labs performance on established tests.

Paul Russo, PhD Research Assistant Professor Email: prusso@gmu.edu Pauls research focuses on using multiple reaction monitoring mass spectrometry (MRM-MS) to quantitate and validate potential biomarkers for diseases including cancer, heart disease, and schizophrenia. After potential biomarkers are discovered by other mass spectrometry methods, Paul uses MRM-MS to validate and quantify data using larger sample sets. Paul is also developing a method using MRM-MS to quantitate human growth hormone (hGH) in human blood and urine to identify athletes who have doped.

Amy VanMeter Adams, MS Research Specialist Email:avanmete@gmu.edu Amys research focuses on using laser capture microdissection, western blotting and reverse phase protein microarray technology to investigate the phosphorylation events in signaling pathways for the discovery of new rational drug targets and mapping protein pathways which can be applied to disease diagnosis and prognosis Amy also directs The Aspiring Scientists Summer Internship Program that engages high school and undergraduate students in cutting edge scientific research related to Proteomics, Genomics, Neuroscience, Biochemistry, Chemistry, Biodefense, Nanotechnology, Bioinformatics, Computer Science, Physics and Environmental Science.

Julia Wulfkuhle, PhD Research Professor Email: jwulfkuh@gmu.edu Dr. Wulfkuhle has more than 10 years of experience in human tissue processing and preparation for Laser Capture Microdissection and in the field of functional signal pathway profiling of human cells and tissues using Reverse Phase Protein Microarray (RPMA) technology. She has contributed to methods development for sample preparation, printing, staining, image capture and analysis and has also been involved in the establishment of a set of reference standards and calibrators for RPMAs that will be used in the transition of this technology into a calibrated assay that can be used for standardization and quantification of staining intensities across arrays and between experiments. Dr. Wulfkuhles research interests include proteomic profiling of solid tumor tissues, including breast, prostate, lung and brain, for designing personalized therapeutic strategies, and identification of signaling mechanisms underlying resistance to targeted therapeutics.

Weidong Zhou, PhD Research Assistant Professor Email: wzhou@gmu.edu Weidong analyzes serum, tissue and cell lines using liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) for biomarker discovery relevant to cancer, Alzheimers disease, infectious disease, schizophrenia, and atrial fibrillation.

Follow this link:
CAPMM Team | Center for Applied Proteomics and Molecular ...

NOD.Cg-Prkdc Il2rg Tg(HLA-A2.1)1Enge/SzJ …

By Stell Cell Research

JAX Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSONs prior written authorization.

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSONs MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Read this article:
NOD.Cg-Prkdc Il2rg Tg(HLA-A2.1)1Enge/SzJ ...

Hair Restoration Treatment Uses Novel Stem Cell Therapy …

By Stem Cell Medicine

DALLAS UPTOWN and PLANO, Texas, Oct. 10, 2015 /PRNewswire/ -- For men and women who are just beginning to deal with thinning hair, there is a new way to possibly reverse thinning which does not involve tedious follicle-by-follicle transplantation: platelet-rich plasma (P.R.P.), drawn from one's own blood, optimized, and then re-injected into the scalp. P.R.P. contains a large number of adult stem cells, which are known to stimulate cell growth.

A patients' own platelet-rich blood plasma has been utilized in various cosmetic procedures developed over the past several years to encourage the formation of fresh collagen in the face and hands; now, platelet-rich plasma is being micro-injected into the scalp to stimulate renewed, thicker hair growth.

Medical Director Dr. Jeffrey Adelglass and Director of Dermatology Dr. Elizabeth Houshmand of SKINTASTIC Cosmetic Surgery and Laser Skin Care Centers recently added Platelet Rich Plasma Hair Restoration to their already expansive list of face, body, skincare, and wellness services. While P.R.P. hair growth stimulation can be considered somewhat novel, the cellular science behind it has already expanded into a wide range of medical modalities.

Dr. Adelglass explains, "Working with platelet rich plasma, the overall success is very 'donor-dependent.' We carefully screen our prospective PRP patients for medications and other substances known to inhibit the PRP growth factor's ability to 'take,' such as tobacco. Also, P.R.P. therapy is not effective for treating hair roots that are no longer living."

Consultations at SKINTASTIC for P.R.P. Hair Restoration are recommended with Dr. Houshmand, a double board certified dermatologist, to assess whether or not one is a qualified candidate for this procedure. Dr. Houshmand is also an instructor who teaches the technique to other physicians. She briefly explains the procedure: "P.R.P. Hair Growth is an outpatient procedure at SKINTASTIC. Our technician draws a single vial of blood, and we spin it up in the centrifuge to separate the plasma, which is then prepared and immediately micro-injected into the treatment areas. Patients may see their first noticeable hair growth several weeks after their treatment."

Those interested in learning more about P.R.P. Hair Growth Therapy should make an appointment at SKINTASTIC Cosmetic Surgery and Laser Skin Centers in Dallas Uptown or Plano, Texas by calling (972) 620-3223, or at skintastic.com.

Media: Contact Jeffrey Adelglass, M.D., F.A.C.S. at (214) 392-8830, or jeffadel@gmail.comand Elizabeth Houshmand MD FAAD, FABIM at (484) 838-0487 or elizabeth2713@hotmail.com.

Doctors Adelglass or Houshmand may be available for interview on advances in cosmetic surgery and new beauty technologies, or to speak to groups regarding this or other related topics.

SOURCE SKINTASTIC Cosmetic Surgery and Laser Skin Care Centers

RELATED LINKS http://skintastic.com

More:
Hair Restoration Treatment Uses Novel Stem Cell Therapy ...

→←